Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons

The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one-cycle infection assay. Analysis of PA sequences o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gubareva, Larisa V, Mishin, Vasiliy P, Patel, Mira C, Chesnokov, Anton, Nguyen, Ha T, De La Cruz, Juan, Spencer, Sarah, Campbell, Angela P, Sinner, Mallory, Reid, Heather, Garten, Rebecca, Katz, Jackie M, Fry, Alicia M, Barnes, John, Wentworth, David E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2019
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344838/
https://www.ncbi.nlm.nih.gov/pubmed/30670144
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.3.1800666
Descripción
Sumario:The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one-cycle infection assay. Analysis of PA sequences of 6,891 influenza A and B viruses collected during 2016/17 and 2017/18 seasons showed amino acid substitutions: I38L (two A(H1N1)pdm09 viruses), E23G (two A(H1N1)pdm09 viruses) and I38M (one A(H3N2) virus); conferring 4–10-fold reduced susceptibility to baloxavir.

Ejemplares similares